LP14 : A Phase 3, Randomised, Open-Label Study to Evaluate the Efficacy and Safety of 8 and 12 Weeks of Simeprevir (SMV) Plus Sofosbuvir (SOF) in Treatment-Naïve and -Experienced Patients with Chronic HCV Genotype 1 Infection Without Cirrhosis: Optimist-1
Journal of Hepatology（2015）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined